Survodutide shows weight loss and glycemic gains in phase 3 trial
Boehringer Ingelheim's glucagon/GLP-1 dual agonist reported improvements on both body weight and blood sugar endpoints in late-stage testing.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 7 05:56 ETSource: PharmaTimes
The wire
- 01PharmaTimes reports phase 3 results for survodutide, a dual glucagon/GLP-1 receptor agonist, showing weight loss alongside glycemic improvement.
- 02A second dual-agonist entrant would widen incretin prescribing options beyond semaglutide and tirzepatide for clinicians and compounding-era telehealth operators tracking supply.
- 03Full endpoint data, tolerability detail and regulatory filing timelines remain to be confirmed from the complete trial presentation.
From the source
Read at pharmatimes.comSurvodutide delivers weight loss and glycemic gains in phase 3 trial
